<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548286</url>
  </required_header>
  <id_info>
    <org_study_id>144BE15015</org_study_id>
    <nct_id>NCT02548286</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers(B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of CKD-330
      (fixed-dose combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) with
      coadministration of the two separate drugs in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(Maximum Plasma Concentration) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt(Area Under the Plasma Concentration-time curve) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax(Maximum Plasma Concentration) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt(Area Under the Plasma Concentration-time curve) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax(Time to reach the maximum concentration) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β(Time for C max to drop in half) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F(Clearance/Bioavailability) of Candesartan</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax(Time to reach the maximum concentration) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β(Time for C max to drop in half) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F(Clearance/Bioavailability) of Amlodipine</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan and Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-330</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-330 8/5mg, PO, 1day or 22day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 8mg</intervention_name>
    <description>PO, 1day or 22day</description>
    <arm_group_label>Candesartan and Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>PO, 1day or 22day</description>
    <arm_group_label>Candesartan and Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 8/5mg</intervention_name>
    <description>PO, 1day or 22day</description>
    <arm_group_label>CKD-330</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer in the age of 19-45

          2. Body weight ≥ 55 kg and in the range of calculated IBW ±20%

          3. Subject without a hereditary problems, chronic disease and morbid symptom

          4. Suitable clinical laboratory test values

          5. Subject who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Clinically significant disease with hepatobiliary, nephrological, neurologic,
             respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal,
             immune, otorhinolaryngological, cardiovascular system

          2. Gastrointestinal disease or gastrointestinal surgery

          3. History of significant hypersensitivity reaction of amlodipine, candesartan, calcium
             channel blocker, angiotensin II receptor blocker or other drugs

          4. Galactose intolerance

          5. Sitting systolic blood pressure ≥ 140 mmHg or&lt; 90 mmHg, sitting diastolic blood
             pressure ≥ 95 mmHg or &lt; 60 mmHg, pulse ≥ 100 beats per minute

          6. Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin &gt; 2 x upper
             limit of normal range

          7. Serum Creatinine &gt; upper limit of normal range

          8. Drug abuse

          9. Subject treated metabolizing enzyme inducers or inhibitors within 1 month

         10. Subject treated ethical the counter or herbal medicine within 2 weeks,
             over-the-counter or vitamin within 1 week

         11. Subject treated Investigational product(include Bioequivalence test) within 3 months

         12. Whole blood donation within 2 months, component blood donation or blood transfusion
             within 1 month

         13. Continuously taking Alcohol &gt; 21 units/week

         14. Cigarette &gt; 10 cigarettes/day

         15. Subjects with planning of dental treatment or any surgery

         16. Another clinical condition in judgement of investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Healthy male volunteer</keyword>
  <keyword>Candesartan, Amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

